Product Overview
Retatrutide 10mg Canada - LY3437943 Research Peptide
Retatrutide 10mg from Precision Synthetics Canada is a lyophilized research peptide supplied in a sealed 3 mL glass vial for laboratory research and analytical use.
Retatrutide, also known as LY3437943 or LY-3437943, is studied as a triple receptor agonist across the glucagon, GIP, and GLP-1 receptor pathways. Its multi-incretin profile has made it a high-interest compound in research involving body-weight models, metabolic signaling, receptor activity, glycemic endpoints, energy expenditure, and body-composition research.
Precision Synthetics Canada takes a safety-first approach to research peptide supply. Each released batch is supported by Janoshik source-lab documentation, independent Testide Canada Laboratory verification, and LAL endotoxin screening through Testide for supported batches. This gives Canadian research buyers more than a purity percentage by adding visibility into identity, purity, batch traceability, and endotoxin screening.
Key Highlights
- 10 mg lyophilized Retatrutide per vial
- Also known as Retatrutide, LY3437943, and LY-3437943
- Triple GCGR / GIPR / GLP-1R receptor agonist research compound
- Sealed 3 mL glass vial with batch-labeled traceability
- Janoshik Laboratory source-lab documentation
- Independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada
- LAL endotoxin screening through Testide for added batch-quality review
- COA access for supported batches
- Ships from Vancouver, Canada
LAL Endotoxin Screening + Dual Third-Party Review
Purity matters, but it is only one part of responsible batch review. Precision Synthetics Canada puts extra emphasis on LAL endotoxin screening because many research peptide listings stop at HPLC purity alone and do not show this additional endotoxin-screening layer.
For supported batches, Retatrutide research material is reviewed through a layered documentation model: Janoshik source-lab documentation, independent Testide Canada Laboratory verification, and LAL endotoxin screening through Testide. This gives research buyers more than a single supplier document by adding visibility into identity, purity, traceability, chromatogram data, report date, sample reference, batch linkage, endotoxin screening, and verifiable report information when available.
- LAL endotoxin screening: an added quality-control datapoint used to assess bacterial endotoxin presence in the submitted sample.
- Janoshik Laboratory: source-lab testing documentation connected to the originating production batch, including identity and purity information.
- Testide Canada Laboratory: independent verification arranged by Precision Synthetics Canada before supported batches are released, including LAL endotoxin screening where applicable.
COA Transparency
COA access is provided for supported batches through batch-linked documentation, QR code access, or a product documentation page. For more information, visit COA Transparency.
Some Janoshik source-lab COAs may include limited redactions to protect upstream laboratory confidentiality and prevent unauthorized or unsolicited contact with source-lab partners. These redactions may apply to identifying or commercially sensitive details and are not intended to obscure analytical results.
Research Profile
Retatrutide is studied as a multi-incretin research peptide because of its activity across three receptor pathways:
| Pathway | Research Relevance |
|---|---|
| GCGR | Glucagon receptor pathway research |
| GIPR | Glucose-dependent insulinotropic polypeptide receptor research |
| GLP-1R | Glucagon-like peptide-1 receptor research |
Common research areas include:
- Body-weight and obesity research models
- Triple glucagon/GIP/GLP-1 receptor agonism
- Multi-incretin pathway signaling
- cAMP signaling and receptor potency studies
- Receptor selectivity and comparative activity
- Glycemic endpoint research
- Insulin-response and metabolic biomarker models
- Energy expenditure and food-intake research models
- Body weight, fat mass, and lean mass partitioning models
- Comparative pharmacology involving semaglutide, tirzepatide, and other incretin analogs
- Analytical identity, purity, endotoxin screening, and batch-to-batch review
Retatrutide is sometimes searched informally as "triple GLP" or "GLP-3", but the accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.
Review the Retatrutide research papers page for published study references, mechanism notes, and endpoint data.
Product Details
| Specification | Details |
|---|---|
| Product name | Retatrutide 10mg |
| Brand | Precision Synthetics Canada |
| Synonyms | LY3437943, LY-3437943 |
| Product type | Research peptide |
| Research class | Triple glucagon/GIP/GLP-1 receptor agonist |
| Net content | 10 mg per vial |
| Format | Lyophilized material |
| Appearance | White to off-white lyophilized material |
| Container | Sealed 3 mL glass vial |
| Approximate vial weight | 0.005 kg, about 5 g |
| Lot/batch ID | Recorded on vial label |
| Testing model | Janoshik source-lab documentation + Testide Canada Laboratory verification |
| Endotoxin screening | LAL endotoxin screening through Testide Canada Laboratory for supported batches |
| COA access | Batch-linked documentation for supported batches |
| Shipping origin | Vancouver, Canada |
| Shipping availability | Canada only |
| Intended use | Research use only |
Compound Identity
| Field | Information |
|---|---|
| Compound | Retatrutide |
| Synonyms | LY3437943, LY-3437943 |
| CAS | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | Approximately 4731.35 g/mol |
| Research category | Long-acting multi-incretin analog |
| Receptor pathways | GCGR, GIPR, GLP-1R |
Canadian Shipping
Orders ship from Vancouver, Canada. Shipping is currently available within Canada only.
Intended Use
Retatrutide 10mg is supplied for laboratory research, analytical reference work, assay development, and non-clinical research applications.
FAQ
What is Retatrutide?
Retatrutide, also known as LY3437943 or LY-3437943, is a synthetic research peptide studied for activity across the glucagon, GIP, and GLP-1 receptor pathways.
Is this Retatrutide third-party tested?
Yes. Each released batch is supported by Janoshik source-lab documentation and independent Testide Canada Laboratory verification arranged by Precision Synthetics Canada.
Does this product include LAL endotoxin screening?
Released batches include LAL endotoxin screening through Testide Canada Laboratory for supported batches. This adds another quality-control datapoint for research buyers.
Does this product include a COA?
Applicable released batches are supported by batch-linked COA documentation. COA access may be provided through a QR code, report link, or batch documentation page.
Where does this product ship from?
Retatrutide 10mg ships from Vancouver, Canada, with shipping currently available within Canada only.
Is Retatrutide the same as GLP-3?
No. "GLP-3" is an informal search term sometimes used online. The accurate research description is triple glucagon/GIP/GLP-1 receptor agonist.